The CRISPR/Cas9 system is a recently developed genome editing technique. In this study, we used a modified CRISPR system, which employs the fusion of inactive Cas9 (dCas9) and the FokI endonuclease 
defense mechanism against bacteriophages, and is currently being used for site-specific genome editing. It is composed of a single-guide RNA (sgRNA) containing a 20 nt sequence that targets a specific genomic site and one Cas9 nuclease that enables the cleavage of genomic DNA. The DSBs then stimulate the DNA repair pathway through non-homologous end joining (NHEJ) and HDR. Of these mechanisms, HDR can generate the desired sequence replacement at the DSBs through the usage of a donor DNA template, which corrects the specific variant within the genome 5 . Several studies have recently reported encouraging results using CRISPR/Cas9 for successful therapeutic concepts, such as Duchenne muscular dystrophy and retinitis pigmentosa in vitro and in vivo [6] [7] [8] [9] [10] . However, there are still two major challenges in the CRISPR/Cas9-mediated genome correction: frequent off-target effects and low HDR efficiency 5, 11, 12 . To overcome these problems, different strategies were adopted in this study. First, we chose the CRISPR RNA-guided FokI nuclease system (FokI-dCas9 system) [13] [14] [15] instead of the CRISPR/Cas9 system as the specific genome editing tool. The FokI-dCas9 system is composed of two distinct sgRNAs and FokI-dCas9 nuclease, which is a fusion of inactive Cas9 (dCas9) and the FokI endonuclease. The FokI-dCas9 system differs from CRISPR/Cas9 in that the simultaneous binding of two distinct FokI-dCas9:sgRNAs is required. Moreover, we employed 3-(N-benzylsulfamoyl)-4-97 bromo-N-(4-bromophenyl)benzamide (RS-1), an HDR enhancer 16, 17 , as a RAD51-stimulatory compound 18 . By this means, we successfully performed a genetic repair of the c.1222C>T PAH variant, which for the first time corrected the point variant and rescued both PAH protein expression and activity.
Results
Establishment of the PAH_c.1222C>T COS-7 cell line as an in vitro PKU model. The PAH_c.1222C>T variant was introduced into COS-7 cells by transfection with an appropriately modified vector DNA. Single clones were sub-cultured for at least 15 passages. Sanger sequencing analysis proved that the "T" point variant was appropriately located in PAH (Fig. 1a) . Reverse transcription PCR (RT-PCR) confirmed that PAH_c.1222C>T was expressed in the transfected COS-7 cells at the RNA level at a similar level as the wild-type protein used in control; untransfected COS-7 cells exhibited no PAH RNA (Fig. 1b) . Concurrently, Western blot analysis with an antibody against the wild-type protein (PAH_WT) revealed a basically complete loss of the PAH protein in the cells transfected with the mutated gene version (Fig. 1c) .
The PAH_c.1222C>T variant was corrected using the FokI-dCas9 system. The FokI-dCas9 system is different from the CRISPR/Cas9 system insofar as only binding of a FokI-dCas9 dimer can cleave DNA (Fig. 2a) . After electroporation of COS-7 cells with expression vectors of the FokI-dCas9 gene and the sgRNA, flow cytometry analysis showed that approximately 18.4% of cells co-expressed them simultaneously (Fig. 2b) . In presence of RS-1, PAH expression in PAH_c.1222C>T COS-7 cells treated with 0.5 or 1 nM of the single-stranded oligodeoxynucleotide (ssODN) that represents the replacement sequence was significantly higher than the PAH expression of PAH_c.1222C>T COS-7 cells that were not transfected with the vectors. A lower ssODN concentration had no apparent effect on PAH expression (Fig. 2c) . Furthermore, liquid chromatography-electrospray ionization tandem mass spectrometry was employed to evaluate the PAH activity after repair (Fig. 2d) , confirming the results of the Western blot analysis. Sanger sequencing analysis was performed to confirm the correction in all groups. The 1 nM ssODN and 0.5 nM ssODN groups showed double-peaks at the corrected position regardless of RS-1 treatment, demonstrating the presence of both a "T" and a "C" at the PAH_c.1222C>T variant in the cell population ( Supplementary Fig. 1a ). To examine the correction rate, we amplified by PCR target DNA from the 1 nM ssODN with RS-1 treatment group and verified the sequence by TA-cloning. Sequence analysis of the DNA of 30 colonies showed that 8 of them (26.7%) contained the correct "C" (Fig. 2e) . To assess the possible off-targeting introduced by FokI-dCas9-directed cleavage, two potential off-target sites were predicted by CasOT (Supplementary Table 1 ). Both potential sites were analyzed together with the PAH gene on-target site by Sanger sequencing. None of the analyzed regions showed evidence of off-target cleavage (data not shown). 
Discussion
Although the restriction of dietary Phe and/or supplementation with BH 4 can substantially alleviate clinical symptoms of PKU, patients do not manage to maintain dietary treatment for life. They suffer from impaired neuropsychological and partly from intellectual function and PKU women are at risk for the maternal PKU syndrome. The ideal approach to treating this disease would be a correction of the PAH variant. PKU gene therapy has been developed over the past two decades using an animal model. Researchers delivered the wild-type PAH gene to tissues with an adeno-associated virus (AAV) vector. However, the temporary recovery of PAH activity, risks associated with the AAV vector or a very low gene transfer rate in the past limited the development of this treatment option 19, 20 . Ongoing research is focused on new genome editing technologies that can correct genomic variants. Therefore, in this study the FokI-dCas9 system was chosen to correct with high accuracy and efficiency the most common PAH variant in cells.
The CRISPR/Cas9 system stimulates DNA repair mechanisms such as NHEJ and HDR. NHEJ leads to random deletion or insertion variants close to the DSB site, resulting in gene knock out, while HDR can generate a desired sequence replacement at the DSB by donating a DNA template, resulting in gene correction. Despite the tremendous potential of the original CRISPR/Cas9 system 21 , several challenges still limit its application to gene therapy. For example, the short 20 bp target sequence required in the sgRNA, of the commonly used SpCas9 system may cause off-target effects elsewhere in the genome 12 . Moreover, NHEJ is the dominant mechanism for repairing DSBs after DNA cleavage in mammals, preventing gene correction by HDR. Thus, new strategies that avoid off-target effects and increase the HDR:NHEJ ratio are needed 22 . The FokI-dCas9 system can greatly improve the specificity of genome editing in vitro and in vivo. In contrast to the CRISPR/Cas9 system, it requires dimerization of the FokI-dCas9-sgRNA complex, meaning that monomeric FokI-dCas9-sgRNA is unable to cut the DNA strand 14 . Three rules are used in designing a specific FokI-dCas9-sgRNA complex that retains high cleavage efficiency. First, the pair of sgRNAs should bind to sense and antisense strands. Second, two distinct FokI-dCas9-sgRNA-binding "half-sites" must be located close to the targeted genomic position, and third, the FokI-dCas9-sgRNA complex requires a particular orientation. Generally, having protospacer adjacent motif (PAM) sequences for the two distinct FokI-dCas9-sgRNA complexes located on the outer boundaries of the target site ("PAM-out" orientation) is superior to having them connected directly to the spacer sequence ("PAM-in" orientation). In addition, the spacer length between two PAM sequences has limitations. Fourteen to 17 bp of spacer length exhibit higher on-target cleavage efficiency than other spacer lengths between 0 to 31 bp 15 . Based on these rules, this study chose the FokI-dCas9-sgRNA complex with a "PAM-out" orientation and spacer length of 17 bp. Moreover, it is worth noting that while a single FokI-dCas9-sgRNA can bind elsewhere in the genome, it cannot cleave DNA and cause off-target effects. In addition, FokI-dCas9 targets DNA sites with more than 140-fold higher specificity than normal SpCas9 and higher specificity than Cas9 nickases, which only cut single DNA strands throughout the genome 23 . Although besides FokI-dCas9, strategies like Cas9 nickases or high-fidelity eSpCas9 variants 24 , 25 can be adopted to enhance Cas9 specificity, we selected the FokI-dCas9 system to correct the PAH variant for its dual advantage of high specificity 14 and potential improvement of HDR efficiency by DNA template preservation. It is generally known that the generation of HDR requires a large amount of DNA template. In the CRISPR/Cas9, eSpCas9 or Cas9 nickases systems, the DNA template can be cut by nucleases, even if an ssODN is used as the repair template. However, the FokI-dCas9-sgRNA complex cannot cleave the ssODN template as two distinct FokI-dCas9-sgRNA complexes have to bind to different DNA strands. Therefore, the CRISPR RNA-guided FokI nucleases system ensures a rich source of repair template during the HDR process. To further enhance HDR efficiency, a small-molecule drug was used in our study. The potent NHEJ inhibitor 5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol (SCR-7) and the HDR enhancer RS-1, can be used to improve nuclease-mediated HDR efficiency 16, 26 . RS-1 shows greater potential than SCR-7 in improving the HDR rate in vivo 17 . Our study found that, after electroporation with the FokI-dCas9-sgRNA complex, the PAH_c.1222C>T COS-7 cells remaining in RS-1 culture medium showed more than twice as much PAH activity as negative controls. Also, the PAH expression of the RS-1 group was significantly higher than cells grown without RS-1. The 26.7% correction rate can be expected to provide a clinically sufficient therapeutic effect, as normal development has been reported in patients with PAH activities as low as 8.7-34.5% of normal 27 . RS-1 can increase knock-in efficiency by two-to five-fold in both the TALEN-and Cas9-mediated knock-in systems 17 . We found a similar improvement in HDR efficiency in the FokI-dCas9 system.
Using LC-ESI-MS-MS, we could determine in PAH_c.1222C>T COS-7 cells electroporated with the sgRNA plasmid, FokI-dCas9 plasmid and 1 nM ssODN and cultured in RS-1 a PAH activity of 22.1% compared to 8.8% in the control group. The goal of this study was not only the genetic repair of the PAH variant, but also the rescue of PAH activity after correction. The rescue of PAH activity demonstrates that our strategy is a promising approach for PKU treatment.
In conclusion, this study indicates that the FokI-dCas9 system is a suitable, specific and effective genome editing technique for correcting a major PAH variant that causes PKU. This highlights its tremendous potential for the precise treatment of also other inherited metabolic diseases.
Methods
Construction of the PAH_c.1222C>T vector and establishment of the PAH_c.1222C>T COS-7 cell line. A wild-type PAH cDNA was cloned into the pLVX-EF1α -IRES-Puro vector (Clontech) using Xbal and BamHI cleavage (Thermo Fisher Scientific) after the amplification of cDNA from the pCMV-FLAG-PAH wild-type plasmid. The PAH_c.1222C>T variant in the PAH cDNA sequence was introduced by site-directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and confirmed by Sanger DNA sequencing (GATC Biotech). EF1α forward and IRES reverse sequencing primers (Thermo Fisher Scientific) were used to sequence the PAH_c.1222C>T variant.
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6 cells were seeded and cultured in one dish of 10 cm diameter. The transfection of one dish utilized 45 μ L Fugene HD reagent (Promega) and 15 μ g PAH_c.1222C>T plasmid or the plasmid with the wild-type sequence as a control. Forty-eight hours post transfection, the growth medium was replaced with complete growth medium containing 10 μ g/mL puromycin as the selective agent. After the non-transfected COS-7 cells had died, a single PAH_c.1222C>T COS-7 clone was isolated using limiting dilution cloning technique performed in 96-well plates with 10 μ g/mL puromycin remaining in the culture medium. The clone was characterized through RT-PCR, and expanded in 75 cm 2 cell culture flasks.
Construction of the CRISPR RNA-guided FokI system plasmids and the HDR donor. The IRES-ZsGreen1 fragment of the pLVX-EF1α -IRES-ZsGreen1 vector (Clontech, Mountain View, USA), was used to construct by means of the Megaprimer PCR method 28 the FokI-dCas9-IRES-ZsGreen1 plasmid (Supplementary Fig. 1b) .
gRNAs, targeting the PAH_c.1222C>T variant were designed with the E-CRISP software tool (www.e-crisp.org) 29 . One suitable gRNA pair, which is composed of two separate gRNAs, was chosen as previously described 15 . gRNA pairs should be located on either side of the target in the PAM-out orientation and contain spacer of 14-17 bp in length. The final sgRNA expression fragment (Supplementary Table 2 ) was synthesized using gBlocks (Integrated DNA Technologies). It contains two separate U6 promoters, gRNAs and tracrRNAs, but is free of any 5′ modifications. The synthesized sgRNA fragment was cloned into the pRSI9 vector (Cellecta) using Gibson Assembly Cloning (New England Biolabs) resulting in the pRSI9-1222sgRNA plasmid (Supplementary Fig. 1c) .
The ssODN was synthesized using an HDR template from Integrated DNA Technologies. The homology arm of the HDR template located on the 5′ end of the PAH_c.1222C>T variant position is 71 nt and the arm on the 3′ end is 111nt (Supplementary Table 2 ). Measurement of PAH activity by liquid chromatography-electrospray ionization tandem mass spectrometry. The PAH activity of the cell lysates was measured using previously described methods 30 . In brief, 5 μ L (containing 5-10 μ g of total protein) of cell homogenate obtained from PAH_c.1222C>T COS-7 cells after electroporation was mixed with 0.1 M Na-HEPES buffer, 2 μ g catalase and 1 M L-Phe and incubated for 5 min. One μ M Fe(NH 4 ) 2 (SO 4 ) 2 was added into the mixture for one minute. PAH assay reaction was started by adding 200 μ M BH 4 and then incubated at 25 °C for 15 min. The reaction was stopped by adding 50 μ L of 2% (w/v) acetic acid in ethanol. Then, the PAH samples were prepared for liquid chromatography-electrospray ionization tandem mass spectrometry in accordance with the EZ:faast TM kit manual (Phenomenex). Ten microliters of 100 μ M Phe-d 5 and 10 μ L of 20 μ M Tyr-d 4 were added to 80 μ L PAH assay samples. The Phe and Tyr concentrations were calculated from an internal standard ratio. The specific PAH activity was expressed as mU/mg total protein, with mU equal to nmol Tyr produced. The PAH activity of PAH_wild-type COS-7 cells was used as a positive control and set at 100%.
Electroporation of
Immunoquantification by Western blot analysis. Small amounts (10-15 μ g) of protein lysate from the PAH activity assay were used to detect PAH expression by Western blot. An anti-PAH antibody (Merck Millipore) and an anti-β -actin antibody (Santa Cruz Biotechnology) were used as primary antibodies at a 1:5,000 dilution and 1:2,000 dilution, respectively. A goat anti-mouse IgG-HRP conjugated to horseradish peroxidase (Santa Cruz Biotechnology) was used as the secondary antibody for detection at a 1:10,000 dilution. Signals were generated and recorded using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) as described by the manufacturer's instructions.
TA cloning and sequencing of the PAH_c.1222C>T variant reversal. Genomic DNA from electroporated PAH_c.1222C> T COS-7 cells was extracted using NucleoSpin Tissue (Macherey-Nagel) according to the manufacturer's instructions. PCR amplification of the mutated target sites was performed with Q5 High-Fidelity DNA Polymerase (New England Biolabs) at standard conditions. The PCR product was purified with the PureLink PCR Purification Kit (Thermo Fisher Scientific). Poly-A tailing of the purified DNA was completed using Taq Polymerase (Qiagen), followed by cloning into plasmid pMD19-T (Clontech). Upon transformation into E. coli cells and colony growth, DNA was isolated from individual colonies and analyzed by Sanger sequencing, using EF1α forward and IRES reverse sequencing primers.
